Is BPC-157 legal?
Not as a drug. BPC-157 has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. An FDA advisory committee recommended it for pharmacy compounding in July 2026, but FDA has not acted, so pharmacies still cannot compound it.
DESCRIBES THE LAW · NOT LEGAL ADVICE · NO DOSING INFORMATION
Federal, compounding and sport status
CHECKED 12 OCT 2026Federal status
- Jul 23, 2026 · recommended · 8 yes, 6 no, 1 abstention (law-firm reports; FDA has posted no tally) · SOURCE ↗
- Jun 12, 2023 — Warrior Labz SARMs (cited: bpc-157, tb-500) · LETTER ↗
Sport-body status
What we couldn’t verify
State rules
2 STATESOhio's Board of Pharmacy states that peptides such as BPC-157 'cannot be compounded because it violates federal and state law', and that clinics and med spas may not possess any drug labelled 'for research purposes only', whatever the patient consents to.
Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound BPC-157: in Indiana the ingredient could not be research grade.
- Indiana Senate Enrolled Act 282 (Public Law 136-2026), signed 5 Mar 2026 ↗ · verified Oct 12, 2026
- SEA 282 enrolled text ↗ · verified Oct 12, 2026
In the other states we found nothing that names BPC-157; federal law applies.
What changed at the last check
7 CHANGES| Date | Field | Was | Now | Why |
|---|---|---|---|---|
| 12 Oct 2026 | WADA 2027 | 2027 List not yet published | prohibited (S0), unchanged | BPC-157 is still named as an S0 example on the 2027 List published 21 Sep 2026. source ↗ |
| 12 Oct 2026 | 503A Bulks List status | under pcac review | pcac recommended | Not eligible as of 12 Oct 2026. FDA removed BPC-157 from Category 2 on 15 Apr 2026 after the nominations were withdrawn. source ↗ |
| 12 Oct 2026 | FDA Category 2 (safety risk) | under pcac review | not on list | FDA's Category 2 page lists it under 'nominated but withdrawn', not in Category 2. source ↗ |
| 12 Oct 2026 | NV state note | Nevada Board of Pharmacy RAADFest fines (July 2025) involved at least one Category 2 peptide consistent with this class. | removed | Removed. Nevada's Feb 2026 fines over the RAADFest injections were for unlicensed practice and wholesaling; the board's citations do not name this compound. source ↗ |
| 12 Oct 2026 | IN state note | none | added | Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound BPC-157: in Indiana the ingredient could not be research grade. source ↗ |
| 12 Oct 2026 | PCAC review | pending (vote scheduled) | voted yes | PCAC vote on 2026-07-23: 8 yes, 6 no, 1 abstention (law-firm reports; FDA has posted no tally). source ↗ |
| 12 Oct 2026 | HHS stopgap | none | reported, not issued | The Washington Post reported on 7 Oct 2026, citing two unnamed people, an HHS plan to let compounding pharmacies sell some restricted peptides temporarily. No FDA or HHS notice as of 12 Oct 2026. source ↗ |
Questions
3 ANSWERSIs BPC-157 legal in the US?
Not as a drug. BPC-157 has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. An FDA advisory committee recommended it for pharmacy compounding in July 2026, but FDA has not acted, so pharmacies still cannot compound it.
Can a pharmacy compound BPC-157?
Not eligible as of 12 Oct 2026. FDA removed BPC-157 from Category 2 on 15 Apr 2026 after the nominations were withdrawn. On 23 Jul 2026 the PCAC recommended adding it to the 503A Bulks List for ulcerative colitis. The vote is advisory; FDA has published no proposed rule and no interim Category 1 decision. The Washington Post reported on 7 Oct 2026 an unannounced HHS plan to allow temporary compounding of some of these peptides; FDA and HHS had issued nothing as of 12 Oct 2026.
Is BPC-157 banned in sport?
Yes. It is prohibited at all times under WADA 2026 class S0. Named as an S0 example on the 2026 List and again on the 2027 List (in force 1 Jan 2027). Prohibited at all times.
Sources
12 DOCUMENTS- FDA approval record
- DEA controlled-substance schedules
- FDA 503A compounding position
- PCAC review, 23 Jul 2026
- FDA warning letter to Warrior Labz SARMs, 12 Jun 2023
- WADA 2026 Prohibited List
- Ohio Board of Pharmacy, 'Ten common prescriber clinic and medical spa violations' (updated 8 Dec 2025)
- Indiana Senate Enrolled Act 282 (Public Law 136-2026), signed 5 Mar 2026
- SEA 282 enrolled text
- Source for: WADA 2027
- Source for: NV state note
- Source for: HHS stopgap